Healthcare
Axsome Therapeutics, Inc.(AXSM)
Live Price
Offline$250.50
-0.66% today
1Y Change
+144.36%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $11.44B
- Revenue Growth
- +65.5%
- EPS Growth
- +38.6%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Axsome Therapeutics, Inc. (AXSM) is a Healthcare stock with a market cap of $11.44B and listed on NASDAQ. The stock last traded around $250.50 and up 144.4% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +65.5%, EPS growth of +38.6%, a dividend yield of 0.0%. What stands out right now is revenue +65.5%, EPS +38.6%, free cash flow +27.0% with operating margin -24.8% and ROIC -50.8%. Valuation already assumes a fairly strong business story at price/sales 16.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines AXSM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+65.5% vs +7.6% peer median
Operating Margin
Below sector median
-24.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +65.5% and EPS at +38.6%, with operating margin around -24.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.2% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 4, 2026 | โ | -0.3% | -3.2% | -0.7% |
2026 Feb 23, 2026 | -1.4% | -2.8% | -4.8% | -10.3% |
2025 Nov 3, 2025 | -14.6% | -0.6% | +1.5% | +4.7% |
Benchmark Edge
AXSM vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
AXSM
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
AXSM Max Drawdown
-18.50%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for AXSM and SPY.
Company Overview
Axsome Therapeutics, Inc.
NASDAQ Global Market
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
- Leadership
- Herriot Tabuteau
- IPO Date
- Nov 19, 2015
- Employees
- 712
- Street Address
- 22 Cortlandt Street
- Mailing
- New York City, NY, 10007
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 212 332 3241
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 16.2
- Price/Book
- 209.8
Growth
- Revenue
- +65.5%
- EPS
- +38.6%
- Free Cash Flow
- +27.0%
Profitability
- Gross Margin
- 92.6%
- Operating Margin
- -24.8%
- Net Margin
- -26.6%
- ROE
- -260.0%
- ROIC
- -50.8%
Balance Sheet
- Debt/Equity
- 3.97
- Current Ratio
- 1.39
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.